<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01594931</url>
  </required_header>
  <id_info>
    <org_study_id>SP-C-002-05</org_study_id>
    <nct_id>NCT01594931</nct_id>
  </id_info>
  <brief_title>Phase II Dose-ranging Study of Pyronaridine/Artesunate in Adults Patients With Plasmodium Falciparum Malaria</brief_title>
  <official_title>A Randomised, Multi-Centre, Phase II, Dose-ranging Clinical Study to Assess the Safety and Efficacy of Fixed Dose, Orally Administered Pyronaridine and Artesunate (3:1) in Adult Patients With Acute Uncomplicated Plasmodium Falciparum Malaria</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medicines for Malaria Venture</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Shin Poong Pharmaceutical Co. Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Medicines for Malaria Venture</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary trial objective is to determine the clinically effective dose of orally&#xD;
      administered pyronaridine/artesunate (Pyramax®, PA) with a 3:1 ratio to treat adults with&#xD;
      acute, symptomatic, uncomplicated P. falciparum malaria in South East Asia and Africa.&#xD;
      Secondary trial objectives are to determine the safety of once-daily dosing for 3 days of PA&#xD;
      and to explore possible ethnic differences in safety or efficacy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a double-blind, multicentre, randomized, parallel group, dose-finding study of the&#xD;
      efficacy, safety and tolerability of a once-daily 3-day regimen of PA with a 3:1&#xD;
      weight/weight ratio for patients with acute, symptomatic, uncomplicated P. falciparum&#xD;
      malaria. Patients will be recruited from 5 to 7 study sites in endemic regions of South East&#xD;
      Asia and Africa and will be randomized to 1 of 3 treatment groups differing in dosage, with&#xD;
      160 patients per group (n-480). Randomization will be balanced within each study site across&#xD;
      all 3 study groups in pre-assigned treatment blocks.&#xD;
&#xD;
      The first dose will be administered on Day 0 and patients will remain hospitalized for at&#xD;
      least 4 days whilst undertaking the 3-day regimen. Patients will remain near the study site&#xD;
      for a minimum of 7 days or once fever and parasite clearance is confirmed (assessed by 3&#xD;
      negative readings of fever and/or slide).&#xD;
&#xD;
      The primary efficacy end point is the cure rate on Day 28 - the proportion of patients with&#xD;
      PCR-corrected adequate clinical and parasitological response (ACPR). Despite this Day 28 end&#xD;
      point, the relatively long half-life of pyronaridine necessitates follow-up until Day 42. In&#xD;
      the case of adverse events reported and unresolved at Day 42, patients will be followed up&#xD;
      for a further 30 days, or until resolution of the event.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2005</start_date>
  <completion_date type="Actual">April 2006</completion_date>
  <primary_completion_date type="Actual">March 2006</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PCR-Corrected ACPR at Day 28</measure>
    <time_frame>Day 28</time_frame>
    <description>Percentage of subjects with PCR-corrected adequate clinical and parasitological response (ACPR) on Day 28, defined as absence of parasitaemia on Day 28 without the subject's meeting any of the criteria of early treatment failure, late clinical failure, or late parasitological failure</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>PCR-Corrected ACPR at Day 14</measure>
    <time_frame>Day 14</time_frame>
    <description>Percentage of subjects with PCR-corrected adequate clinical and parasitological response (ACPR) on Day 14, defined as absence of parasitaemia on Day 14 without the subject's meeting any of the criteria of early treatment failure, late clinical failure, or late parasitological failure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parasite Clearance Time</measure>
    <time_frame>Thick blood slides were examined every 8 hours until at least 72 hours or until a negative smear was recorded</time_frame>
    <description>Parasite clearance time was defined as the time (in hours) from first dosing to the time of first blood draw with parasite clearance. Parasite clearance is defined as zero presence of parasites for two consecutive negative readings eight hours apart, with confirmed negative reading at 24 hours after the first negative slide</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fever Clearance Time</measure>
    <time_frame>Every 8 hours for at least 72 hours after the first dose</time_frame>
    <description>Fever clearance time was defined as the time (in hours) from first dosing to the first normal reading with fever clearance (2 consecutive assessments without fever (&lt;37.5°C)). The method of temperature measurement was the same (ie, axillary, tympanic, oral or rectal) for each subject. Any subjects with a documented history of fever at inclusion, but who did not subsequently have a documented temperature reading &gt;37.5°C during the 24 hours after initial dosing, were not included in this end point analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parasite Clearance</measure>
    <time_frame>Days 1, 2, and 3</time_frame>
    <description>Parasite clearance is defined as zero presence of parasites for 2 consecutive negative readings 8 hours apart, with confirmed negative reading at 24 hours after the first negative slide. The proportion of subjects with parasite clearance was summarized at Days 1, 2, and 3.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fever Clearance</measure>
    <time_frame>Days 1, 2 and 3</time_frame>
    <description>Fever clearance was defined as a subject without fever for 2 consecutive assessments, plus confirmed normal temperature at 24 hours. The proportion of subjects with fever clearance was summarized at Days 1, 2, and 3.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events (AEs)</measure>
    <time_frame>Day 0 to 42. Subjects experiencing AEs at Day 42 were followed for up to 30 days after the end of study or resolution of the event, whichever was earlier</time_frame>
    <description>An AE was defined as any unfavourable and unintended sign, symptom, syndrome, or illness that developed or worsened during the period of observation in the clinical study</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">477</enrollment>
  <condition>Plasmodium Falciparum Malaria</condition>
  <arm_group>
    <arm_group_label>pyronaridine/artesunate (6:2 mg/kg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>pyronaridine tetraphosphate 6 mg/kg and artesunate 2 mg/kg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>pyronaridine/artesunate (9:3 mg/kg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>pyronaridine tetraphosphate 9 mg/kg and artesunate 3 mg/kg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>pyronaridine/artesunate (12:4 mg/kg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>pyronaridine tetraphsophate 12 mg/kg and artesunate 4 mg/kg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pyronaridine/artesunate</intervention_name>
    <description>Tablets of fixed dose combination of pyronaridine and artesunate at a ratio of 3:1. The tablets were taken daily for 3 days.</description>
    <arm_group_label>pyronaridine/artesunate (12:4 mg/kg)</arm_group_label>
    <arm_group_label>pyronaridine/artesunate (6:2 mg/kg)</arm_group_label>
    <arm_group_label>pyronaridine/artesunate (9:3 mg/kg)</arm_group_label>
    <other_name>Pyramax</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female patients between the age of 15 and 60 years of age inclusive&#xD;
&#xD;
          2. Written informed consent, in accordance with local practice, provided by patient&#xD;
             and/or parent/guardian/spouse. If the patient is unable to write, witnessed consent is&#xD;
             permitted according to local ethical considerations&#xD;
&#xD;
          3. Absence of severe malnutrition (defined as the weight-for-height being below -3&#xD;
             standard deviations or &lt;70% of the median of the NCHS/WHO normalized reference values)&#xD;
&#xD;
          4. Weight of between 35 kg and 75 kg inclusive&#xD;
&#xD;
          5. Presence of acute symptomatic uncomplicated P. falciparum malaria with a diagnosis&#xD;
             confirmed by a positive blood smear with asexual forms of P. falciparum only (i.e. no&#xD;
             mixed infection) plus history of fever within the previous 24 hours or a measured&#xD;
             temperature of ≥37.5°C (depending on method of measurement):&#xD;
&#xD;
               -  the acceptable range is between 1,000 and 100,000 asexual parasite count/μl of&#xD;
                  blood and&#xD;
&#xD;
               -  axillary/tympanic temperature of ≥ 37.5°C or oral/rectal temperature of ≥ 38.0°C&#xD;
&#xD;
          6. Ability to swallow oral medication&#xD;
&#xD;
          7. Ability to comply with study visit schedule: patients will be hospitalised for at&#xD;
             least 4 days and will be required to remain in the vicinity of the trial site for a&#xD;
             minimum of 7 days or until clearance of fever and parasite for at least 24 hours,&#xD;
             whichever is the later. The patient is to return to the study site or to make&#xD;
             themselves available for all scheduled follow up visits, until discharge at Day 42.&#xD;
&#xD;
          8. Females must not be pregnant or lactating and be willing to take measures to not&#xD;
             become pregnant during the study period&#xD;
&#xD;
          9. Willingness and ability to comply with the study protocol for the duration of the&#xD;
             study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients with signs and symptoms of severe/complicated malaria requiring parenteral&#xD;
             treatment according to the World Health Organization Criteria 2000&#xD;
&#xD;
          2. Mixed Plasmodium infection&#xD;
&#xD;
          3. Severe vomiting, defined as &gt;3 times in the 24 hours prior to inclusion in the trial&#xD;
             or inability to tolerate oral treatment&#xD;
&#xD;
          4. Known history or evidence of clinically significant disorders such as cardiovascular&#xD;
             (including arrhythmia), respiratory (including active tuberculosis), hepatic, renal,&#xD;
             gastrointestinal, immunological (including active HIV-AIDS), neurological (including&#xD;
             auditory), endocrine, infectious, malignancy, psychiatric or other clinically&#xD;
             important abnormality (including head trauma).&#xD;
&#xD;
          5. Presence of febrile conditions caused by diseases other than malaria&#xD;
&#xD;
          6. Known history of hypersensitivity, allergic or adverse reactions to pyronaridine or&#xD;
             artesunate or other artemisinins&#xD;
&#xD;
          7. Evidence of use of any other antimalarial agent within 2 weeks prior to the start of&#xD;
             the study confirmed by a negative urine test or using Eggelte dipsticks&#xD;
&#xD;
          8. Positive urine pregnancy test or lactating&#xD;
&#xD;
          9. Received an investigational drug within the past 4 weeks&#xD;
&#xD;
         10. Known active Hepatitis A IgM (HAV-IgM), Hepatitis B surface antigen (HBsAg) or&#xD;
             Hepatitis C antibody (HCV Ab)&#xD;
&#xD;
         11. Known seropositive HIV antibody&#xD;
&#xD;
         12. Liver function tests [ASAT/ALAT levels] &gt;2.5 times upper limit of normal values&#xD;
&#xD;
         13. Known significant renal impairment as indicated by a serum creatinine of ≥ 1.4 mg/dl&#xD;
&#xD;
         14. Previous participation in this clinical trial&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sornchai Looareesuwan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital of Tropical Diseases, Mahidol University, Bangkok, Thailand</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Duong Socheat, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Nat. Centre for Parasitol., Entomol. and Malaria Control, Phnom Penh, Cambodia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Emiliana Tjitra, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Bethesda Hospital, Tomohon, North Sulawasi, Indonesia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kalifa Bojang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>MRC Laboratories, Faraffeni, The Gambia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Patrice Piola, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Epicentre, Mbarara, Uganda</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Oumar Gaye, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre de santé Roi Baudouin, Guediawaye, Senegal</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pailin General Hospital</name>
      <address>
        <city>Pailin</city>
        <country>Cambodia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Farafenni Field Station, c/o MRC Laboratories</name>
      <address>
        <city>Farafenni</city>
        <country>Gambia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bethesday Hospital</name>
      <address>
        <city>Tomohon</city>
        <state>North Sulawesi</state>
        <country>Indonesia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre de santé du roi Baudoin</name>
      <address>
        <city>Guediawaye</city>
        <country>Senegal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Faculty of Tropical Medicine, Mahidol University</name>
      <address>
        <city>Bangkok</city>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MSF Epicentre</name>
      <address>
        <city>Mbarara</city>
        <country>Uganda</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Cambodia</country>
    <country>Gambia</country>
    <country>Indonesia</country>
    <country>Senegal</country>
    <country>Thailand</country>
    <country>Uganda</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>May 7, 2012</study_first_submitted>
  <study_first_submitted_qc>May 8, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 9, 2012</study_first_posted>
  <results_first_submitted>August 20, 2021</results_first_submitted>
  <results_first_submitted_qc>August 20, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">September 17, 2021</results_first_posted>
  <last_update_submitted>October 22, 2021</last_update_submitted>
  <last_update_submitted_qc>October 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>malaria</keyword>
  <keyword>antimalarial</keyword>
  <keyword>artemisinin based combination therapy (ACT)</keyword>
  <keyword>pyronaridine artesunate (Pyramax)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Malaria</mesh_term>
    <mesh_term>Malaria, Falciparum</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Artesunate</mesh_term>
    <mesh_term>Pyronaridine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Group A: Pyronaridine/Artesunate (6:2 mg/kg)</title>
          <description>Pyronaridine tetraphosphate 6 mg/kg and artesunate 2 mg/kg&#xD;
Pyronaridine/artesunate: Tablets of fixed dose combination of pyronaridine and artesunate at a ratio of 3:1</description>
        </group>
        <group group_id="P2">
          <title>Group B: Pyronaridine/Artesunate (9:3 mg/kg)</title>
          <description>Pyronaridine tetraphosphate 9 mg/kg and artesunate 3 mg/kg&#xD;
Pyronaridine/artesunate: Tablets of fixed dose combination of pyronaridine and artesunate at a ratio of 3:1</description>
        </group>
        <group group_id="P3">
          <title>Group C: Pyronaridine/Artesunate (12:4 mg/kg)</title>
          <description>Pyronaridine tetraphsophate 12 mg/kg and artesunate 4 mg/kg&#xD;
Pyronaridine/artesunate: Tablets of fixed dose combination of pyronaridine and artesunate at a ratio of 3:1</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="160"/>
                <participants group_id="P2" count="157"/>
                <participants group_id="P3" count="160">One randomized subject was not treated.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="131"/>
                <participants group_id="P2" count="145"/>
                <participants group_id="P3" count="146"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="29"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="14"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>No defiined</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Group A: Pyronaridine/Artesunate (6:2 mg/kg)</title>
          <description>Pyronaridine tetraphosphate 6 mg/kg and artesunate 2 mg/kg&#xD;
Pyronaridine/artesunate: Tablets of fixed dose combination of pyronaridine and artesunate at a ratio of 3:1</description>
        </group>
        <group group_id="B2">
          <title>Group B: Pyronaridine/Artesunate (9:3 mg/kg)</title>
          <description>Pyronaridine tetraphosphate 9 mg/kg and artesunate 3 mg/kg&#xD;
Pyronaridine/artesunate: Tablets of fixed dose combination of pyronaridine and artesunate at a ratio of 3:1</description>
        </group>
        <group group_id="B3">
          <title>Group C: Pyronaridine/Artesunate (12:4 mg/kg)</title>
          <description>Pyronaridine tetraphsophate 12 mg/kg and artesunate 4 mg/kg&#xD;
Pyronaridine/artesunate: Tablets of fixed dose combination of pyronaridine and artesunate at a ratio of 3:1</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="160"/>
            <count group_id="B2" value="157"/>
            <count group_id="B3" value="160"/>
            <count group_id="B4" value="477"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <population>One subject, who was randomized to the 12+4 mg/kg dose group, did not receive any study medication and was excluded from all populations.</population>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="160"/>
                    <count group_id="B2" value="157"/>
                    <count group_id="B3" value="159"/>
                    <count group_id="B4" value="476"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27.0" spread="10.9"/>
                    <measurement group_id="B2" value="27.4" spread="10.9"/>
                    <measurement group_id="B3" value="28.9" spread="11.4"/>
                    <measurement group_id="B4" value="27.8" spread="11.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <population>One subject, who was randomized to the 12+4 mg/kg dose group, did not receive any study medication and was excluded from all populations.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="160"/>
                    <count group_id="B2" value="157"/>
                    <count group_id="B3" value="159"/>
                    <count group_id="B4" value="476"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="43"/>
                    <measurement group_id="B2" value="37"/>
                    <measurement group_id="B3" value="40"/>
                    <measurement group_id="B4" value="120"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="117"/>
                    <measurement group_id="B2" value="120"/>
                    <measurement group_id="B3" value="119"/>
                    <measurement group_id="B4" value="356"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <population>One subject, who was randomized to the 12+4 mg/kg dose group, did not receive any study medication and was excluded from all populations.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="160"/>
                    <count group_id="B2" value="157"/>
                    <count group_id="B3" value="159"/>
                    <count group_id="B4" value="476"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>White/Caucasian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black</title>
                  <measurement_list>
                    <measurement group_id="B1" value="49"/>
                    <measurement group_id="B2" value="47"/>
                    <measurement group_id="B3" value="48"/>
                    <measurement group_id="B4" value="144"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian/Oriental</title>
                  <measurement_list>
                    <measurement group_id="B1" value="111"/>
                    <measurement group_id="B2" value="110"/>
                    <measurement group_id="B3" value="111"/>
                    <measurement group_id="B4" value="332"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Cambodia</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="160"/>
                    <count group_id="B2" value="157"/>
                    <count group_id="B3" value="160"/>
                    <count group_id="B4" value="477"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Senegal</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="160"/>
                    <count group_id="B2" value="157"/>
                    <count group_id="B3" value="160"/>
                    <count group_id="B4" value="477"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                    <measurement group_id="B2" value="32"/>
                    <measurement group_id="B3" value="30"/>
                    <measurement group_id="B4" value="94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gambia</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="160"/>
                    <count group_id="B2" value="157"/>
                    <count group_id="B3" value="160"/>
                    <count group_id="B4" value="477"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="13"/>
                    <measurement group_id="B4" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Uganda</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="160"/>
                    <count group_id="B2" value="157"/>
                    <count group_id="B3" value="160"/>
                    <count group_id="B4" value="477"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Thailand</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="160"/>
                    <count group_id="B2" value="157"/>
                    <count group_id="B3" value="160"/>
                    <count group_id="B4" value="477"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="80"/>
                    <measurement group_id="B2" value="80"/>
                    <measurement group_id="B3" value="80"/>
                    <measurement group_id="B4" value="160"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Indonesia</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="160"/>
                    <count group_id="B2" value="157"/>
                    <count group_id="B3" value="160"/>
                    <count group_id="B4" value="477"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="21"/>
                    <measurement group_id="B4" value="63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>PCR-Corrected ACPR at Day 28</title>
        <description>Percentage of subjects with PCR-corrected adequate clinical and parasitological response (ACPR) on Day 28, defined as absence of parasitaemia on Day 28 without the subject's meeting any of the criteria of early treatment failure, late clinical failure, or late parasitological failure</description>
        <time_frame>Day 28</time_frame>
        <population>Subjects meeting the following: completed a full course of study medication and had known efficacy endpoints; no missed dose due to vomiting (except at D0); no concom. medication, except acetaminophen; no concom. disease that could have interfered with treatment outcome; no major protocol violation with respect to entry eligibility criteria.</population>
        <group_list>
          <group group_id="O1">
            <title>Group A: Pyronaridine/Artesunate (6:2 mg/kg)</title>
            <description>Pyronaridine tetraphosphate 6 mg/kg and artesunate 2 mg/kg&#xD;
Pyronaridine/artesunate: Tablets of fixed dose combination of pyronaridine and artesunate at a ratio of 3:1</description>
          </group>
          <group group_id="O2">
            <title>Group B: Pyronaridine/Artesunate (9:3 mg/kg)</title>
            <description>Pyronaridine tetraphosphate 9 mg/kg and artesunate 3 mg/kg&#xD;
Pyronaridine/artesunate: Tablets of fixed dose combination of pyronaridine and artesunate at a ratio of 3:1</description>
          </group>
          <group group_id="O3">
            <title>Group C: Pyronaridine/Artesunate (12:4 mg/kg)</title>
            <description>Pyronaridine tetraphsophate 12 mg/kg and artesunate 4 mg/kg&#xD;
Pyronaridine/artesunate: Tablets of fixed dose combination of pyronaridine and artesunate at a ratio of 3:1</description>
          </group>
        </group_list>
        <measure>
          <title>PCR-Corrected ACPR at Day 28</title>
          <description>Percentage of subjects with PCR-corrected adequate clinical and parasitological response (ACPR) on Day 28, defined as absence of parasitaemia on Day 28 without the subject's meeting any of the criteria of early treatment failure, late clinical failure, or late parasitological failure</description>
          <population>Subjects meeting the following: completed a full course of study medication and had known efficacy endpoints; no missed dose due to vomiting (except at D0); no concom. medication, except acetaminophen; no concom. disease that could have interfered with treatment outcome; no major protocol violation with respect to entry eligibility criteria.</population>
          <units>percentage of subjects</units>
          <param>Number</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="101"/>
                <count group_id="O2" value="103"/>
                <count group_id="O3" value="102"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95" lower_limit="89.9" upper_limit="98.0"/>
                    <measurement group_id="O2" value="99" lower_limit="95.5" upper_limit="100.0"/>
                    <measurement group_id="O3" value="99" lower_limit="95.4" upper_limit="99.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PCR-Corrected ACPR at Day 14</title>
        <description>Percentage of subjects with PCR-corrected adequate clinical and parasitological response (ACPR) on Day 14, defined as absence of parasitaemia on Day 14 without the subject's meeting any of the criteria of early treatment failure, late clinical failure, or late parasitological failure</description>
        <time_frame>Day 14</time_frame>
        <population>Subjects meeting the following: completed a full course of study medication and had known efficacy endpoints; no missed dose due to vomiting (except at D0); no concom. medication, except acetaminophen; no concom. disease that could have interfered with treatment outcome; no major protocol violation with respect to entry eligibility criteria.</population>
        <group_list>
          <group group_id="O1">
            <title>Group A: Pyronaridine/Artesunate (6:2 mg/kg)</title>
            <description>Pyronaridine tetraphosphate 6 mg/kg and artesunate 2 mg/kg&#xD;
Pyronaridine/artesunate: Tablets of fixed dose combination of pyronaridine and artesunate at a ratio of 3:1</description>
          </group>
          <group group_id="O2">
            <title>Group B: Pyronaridine/Artesunate (9:3 mg/kg)</title>
            <description>Pyronaridine tetraphosphate 9 mg/kg and artesunate 3 mg/kg&#xD;
Pyronaridine/artesunate: Tablets of fixed dose combination of pyronaridine and artesunate at a ratio of 3:1</description>
          </group>
          <group group_id="O3">
            <title>Group C: Pyronaridine/Artesunate (12:4 mg/kg)</title>
            <description>Pyronaridine tetraphsophate 12 mg/kg and artesunate 4 mg/kg&#xD;
Pyronaridine/artesunate: Tablets of fixed dose combination of pyronaridine and artesunate at a ratio of 3:1</description>
          </group>
        </group_list>
        <measure>
          <title>PCR-Corrected ACPR at Day 14</title>
          <description>Percentage of subjects with PCR-corrected adequate clinical and parasitological response (ACPR) on Day 14, defined as absence of parasitaemia on Day 14 without the subject's meeting any of the criteria of early treatment failure, late clinical failure, or late parasitological failure</description>
          <population>Subjects meeting the following: completed a full course of study medication and had known efficacy endpoints; no missed dose due to vomiting (except at D0); no concom. medication, except acetaminophen; no concom. disease that could have interfered with treatment outcome; no major protocol violation with respect to entry eligibility criteria.</population>
          <units>percentage of subjects</units>
          <param>Number</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="105"/>
                <count group_id="O2" value="107"/>
                <count group_id="O3" value="106"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="97.2" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100" lower_limit="97.2" upper_limit="100.0"/>
                    <measurement group_id="O3" value="100" lower_limit="97.2" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Parasite Clearance Time</title>
        <description>Parasite clearance time was defined as the time (in hours) from first dosing to the time of first blood draw with parasite clearance. Parasite clearance is defined as zero presence of parasites for two consecutive negative readings eight hours apart, with confirmed negative reading at 24 hours after the first negative slide</description>
        <time_frame>Thick blood slides were examined every 8 hours until at least 72 hours or until a negative smear was recorded</time_frame>
        <population>Subjects meeting the following: completed a full course of study medication and had known efficacy endpoints; no missed dose due to vomiting (except at D0); no concom. medication, except acetaminophen; no concom. disease that could have interfered with treatment outcome; no major protocol violation with respect to entry eligibility criteria.</population>
        <group_list>
          <group group_id="O1">
            <title>Group A: Pyronaridine/Artesunate (6:2 mg/kg)</title>
            <description>Pyronaridine tetraphosphate 6 mg/kg and artesunate 2 mg/kg&#xD;
Pyronaridine/artesunate: Tablets of fixed dose combination of pyronaridine and artesunate at a ratio of 3:1</description>
          </group>
          <group group_id="O2">
            <title>Group B: Pyronaridine/Artesunate (9:3 mg/kg)</title>
            <description>Pyronaridine tetraphosphate 9 mg/kg and artesunate 3 mg/kg&#xD;
Pyronaridine/artesunate: Tablets of fixed dose combination of pyronaridine and artesunate at a ratio of 3:1</description>
          </group>
          <group group_id="O3">
            <title>Group C: Pyronaridine/Artesunate (12:4 mg/kg)</title>
            <description>Pyronaridine tetraphsophate 12 mg/kg and artesunate 4 mg/kg&#xD;
Pyronaridine/artesunate: Tablets of fixed dose combination of pyronaridine and artesunate at a ratio of 3:1</description>
          </group>
        </group_list>
        <measure>
          <title>Parasite Clearance Time</title>
          <description>Parasite clearance time was defined as the time (in hours) from first dosing to the time of first blood draw with parasite clearance. Parasite clearance is defined as zero presence of parasites for two consecutive negative readings eight hours apart, with confirmed negative reading at 24 hours after the first negative slide</description>
          <population>Subjects meeting the following: completed a full course of study medication and had known efficacy endpoints; no missed dose due to vomiting (except at D0); no concom. medication, except acetaminophen; no concom. disease that could have interfered with treatment outcome; no major protocol violation with respect to entry eligibility criteria.</population>
          <units>hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="108"/>
                <count group_id="O2" value="109"/>
                <count group_id="O3" value="109"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.9" spread="20.73"/>
                    <measurement group_id="O2" value="33.6" spread="17.08"/>
                    <measurement group_id="O3" value="30.8" spread="14.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Fever Clearance Time</title>
        <description>Fever clearance time was defined as the time (in hours) from first dosing to the first normal reading with fever clearance (2 consecutive assessments without fever (&lt;37.5°C)). The method of temperature measurement was the same (ie, axillary, tympanic, oral or rectal) for each subject. Any subjects with a documented history of fever at inclusion, but who did not subsequently have a documented temperature reading &gt;37.5°C during the 24 hours after initial dosing, were not included in this end point analysis.</description>
        <time_frame>Every 8 hours for at least 72 hours after the first dose</time_frame>
        <population>Subjects meeting the following: completed a full course of study medication and had known efficacy endpoints; no missed dose due to vomiting (except at D0); no concom. medication, except acetaminophen; no concom. disease that could have interfered with treatment outcome; no major protocol violation with respect to entry eligibility criteria.</population>
        <group_list>
          <group group_id="O1">
            <title>Group A: Pyronaridine/Artesunate (6:2 mg/kg)</title>
            <description>Pyronaridine tetraphosphate 6 mg/kg and artesunate 2 mg/kg&#xD;
Pyronaridine/artesunate: Tablets of fixed dose combination of pyronaridine and artesunate at a ratio of 3:1</description>
          </group>
          <group group_id="O2">
            <title>Group B: Pyronaridine/Artesunate (9:3 mg/kg)</title>
            <description>Pyronaridine tetraphosphate 9 mg/kg and artesunate 3 mg/kg&#xD;
Pyronaridine/artesunate: Tablets of fixed dose combination of pyronaridine and artesunate at a ratio of 3:1</description>
          </group>
          <group group_id="O3">
            <title>Group C: Pyronaridine/Artesunate (12:4 mg/kg)</title>
            <description>Pyronaridine tetraphsophate 12 mg/kg and artesunate 4 mg/kg&#xD;
Pyronaridine/artesunate: Tablets of fixed dose combination of pyronaridine and artesunate at a ratio of 3:1</description>
          </group>
        </group_list>
        <measure>
          <title>Fever Clearance Time</title>
          <description>Fever clearance time was defined as the time (in hours) from first dosing to the first normal reading with fever clearance (2 consecutive assessments without fever (&lt;37.5°C)). The method of temperature measurement was the same (ie, axillary, tympanic, oral or rectal) for each subject. Any subjects with a documented history of fever at inclusion, but who did not subsequently have a documented temperature reading &gt;37.5°C during the 24 hours after initial dosing, were not included in this end point analysis.</description>
          <population>Subjects meeting the following: completed a full course of study medication and had known efficacy endpoints; no missed dose due to vomiting (except at D0); no concom. medication, except acetaminophen; no concom. disease that could have interfered with treatment outcome; no major protocol violation with respect to entry eligibility criteria.</population>
          <units>hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="84"/>
                <count group_id="O2" value="93"/>
                <count group_id="O3" value="93"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.8" spread="12.75"/>
                    <measurement group_id="O2" value="24.0" spread="25.99"/>
                    <measurement group_id="O3" value="17.0" spread="12.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Parasite Clearance</title>
        <description>Parasite clearance is defined as zero presence of parasites for 2 consecutive negative readings 8 hours apart, with confirmed negative reading at 24 hours after the first negative slide. The proportion of subjects with parasite clearance was summarized at Days 1, 2, and 3.</description>
        <time_frame>Days 1, 2, and 3</time_frame>
        <population>Subjects meeting the following: completed a full course of study medication and had known efficacy endpoints; no missed dose due to vomiting (except at D0); no concom. medication, except acetaminophen; no concom. disease that could have interfered with treatment outcome; no major protocol violation with respect to entry eligibility criteria.</population>
        <group_list>
          <group group_id="O1">
            <title>Group A: Pyronaridine/Artesunate (6:2 mg/kg)</title>
            <description>Pyronaridine tetraphosphate 6 mg/kg and artesunate 2 mg/kg&#xD;
Pyronaridine/artesunate: Tablets of fixed dose combination of pyronaridine and artesunate at a ratio of 3:1</description>
          </group>
          <group group_id="O2">
            <title>Group B: Pyronaridine/Artesunate (9:3 mg/kg)</title>
            <description>Pyronaridine tetraphosphate 9 mg/kg and artesunate 3 mg/kg&#xD;
Pyronaridine/artesunate: Tablets of fixed dose combination of pyronaridine and artesunate at a ratio of 3:1</description>
          </group>
          <group group_id="O3">
            <title>Group C: Pyronaridine/Artesunate (12:4 mg/kg)</title>
            <description>Pyronaridine tetraphsophate 12 mg/kg and artesunate 4 mg/kg&#xD;
Pyronaridine/artesunate: Tablets of fixed dose combination of pyronaridine and artesunate at a ratio of 3:1</description>
          </group>
        </group_list>
        <measure>
          <title>Parasite Clearance</title>
          <description>Parasite clearance is defined as zero presence of parasites for 2 consecutive negative readings 8 hours apart, with confirmed negative reading at 24 hours after the first negative slide. The proportion of subjects with parasite clearance was summarized at Days 1, 2, and 3.</description>
          <population>Subjects meeting the following: completed a full course of study medication and had known efficacy endpoints; no missed dose due to vomiting (except at D0); no concom. medication, except acetaminophen; no concom. disease that could have interfered with treatment outcome; no major protocol violation with respect to entry eligibility criteria.</population>
          <units>percentage of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="108"/>
                <count group_id="O2" value="109"/>
                <count group_id="O3" value="109"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Clearance rate (%) at Day 1 (24h after first dose)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74" lower_limit="64.8" upper_limit="82.0"/>
                    <measurement group_id="O2" value="82" lower_limit="73.1" upper_limit="88.4"/>
                    <measurement group_id="O3" value="84" lower_limit="76.2" upper_limit="90.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Clearance rate (%) at Day 2 (48h after first dose)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93" lower_limit="85.9" upper_limit="96.7"/>
                    <measurement group_id="O2" value="96" lower_limit="90.9" upper_limit="99.0"/>
                    <measurement group_id="O3" value="95" lower_limit="89.6" upper_limit="98.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Clearance rate (%) at Day 3 (72h after first dose)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96" lower_limit="90.8" upper_limit="99.0"/>
                    <measurement group_id="O2" value="98" lower_limit="93.5" upper_limit="99.8"/>
                    <measurement group_id="O3" value="99" lower_limit="95.0" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Fever Clearance</title>
        <description>Fever clearance was defined as a subject without fever for 2 consecutive assessments, plus confirmed normal temperature at 24 hours. The proportion of subjects with fever clearance was summarized at Days 1, 2, and 3.</description>
        <time_frame>Days 1, 2 and 3</time_frame>
        <population>Subjects meeting the following: completed a full course of study medication and had known efficacy endpoints; no missed dose due to vomiting (except at D0); no concom. medication, except acetaminophen; no concom. disease that could have interfered with treatment outcome; no major protocol violation with respect to entry eligibility criteria.</population>
        <group_list>
          <group group_id="O1">
            <title>Group A: Pyronaridine/Artesunate (6:2 mg/kg)</title>
            <description>Pyronaridine tetraphosphate 6 mg/kg and artesunate 2 mg/kg&#xD;
Pyronaridine/artesunate: Tablets of fixed dose combination of pyronaridine and artesunate at a ratio of 3:1</description>
          </group>
          <group group_id="O2">
            <title>Group B: Pyronaridine/Artesunate (9:3 mg/kg)</title>
            <description>Pyronaridine tetraphosphate 9 mg/kg and artesunate 3 mg/kg&#xD;
Pyronaridine/artesunate: Tablets of fixed dose combination of pyronaridine and artesunate at a ratio of 3:1</description>
          </group>
          <group group_id="O3">
            <title>Group C: Pyronaridine/Artesunate (12:4 mg/kg)</title>
            <description>Pyronaridine tetraphsophate 12 mg/kg and artesunate 4 mg/kg&#xD;
Pyronaridine/artesunate: Tablets of fixed dose combination of pyronaridine and artesunate at a ratio of 3:1</description>
          </group>
        </group_list>
        <measure>
          <title>Fever Clearance</title>
          <description>Fever clearance was defined as a subject without fever for 2 consecutive assessments, plus confirmed normal temperature at 24 hours. The proportion of subjects with fever clearance was summarized at Days 1, 2, and 3.</description>
          <population>Subjects meeting the following: completed a full course of study medication and had known efficacy endpoints; no missed dose due to vomiting (except at D0); no concom. medication, except acetaminophen; no concom. disease that could have interfered with treatment outcome; no major protocol violation with respect to entry eligibility criteria.</population>
          <units>percentage of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="108"/>
                <count group_id="O2" value="109"/>
                <count group_id="O3" value="109"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Clearance rate (%) at Day 1 (24h after first dose)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96" lower_limit="90.8" upper_limit="99.0"/>
                    <measurement group_id="O2" value="91" lower_limit="83.8" upper_limit="95.5"/>
                    <measurement group_id="O3" value="96" lower_limit="90.9" upper_limit="99.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Clearance rate (%) at Day 2 (48h after first dose)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99" lower_limit="94.9" upper_limit="100.0"/>
                    <measurement group_id="O2" value="96" lower_limit="90.9" upper_limit="99.0"/>
                    <measurement group_id="O3" value="100" lower_limit="96.7" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Clearance rate (%) at Day 3 (72h after first dose)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99" lower_limit="94.9" upper_limit="100.0"/>
                    <measurement group_id="O2" value="96" lower_limit="90.9" upper_limit="99.0"/>
                    <measurement group_id="O3" value="100" lower_limit="96.7" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adverse Events (AEs)</title>
        <description>An AE was defined as any unfavourable and unintended sign, symptom, syndrome, or illness that developed or worsened during the period of observation in the clinical study</description>
        <time_frame>Day 0 to 42. Subjects experiencing AEs at Day 42 were followed for up to 30 days after the end of study or resolution of the event, whichever was earlier</time_frame>
        <population>The safety population includes all subjects who were randomized and received any study medication, regardless of the amount.</population>
        <group_list>
          <group group_id="O1">
            <title>Group A: Pyronaridine/Artesunate (6:2 mg/kg)</title>
            <description>Pyronaridine tetraphosphate 6 mg/kg and artesunate 2 mg/kg&#xD;
Pyronaridine/artesunate: Tablets of fixed dose combination of pyronaridine and artesunate at a ratio of 3:1</description>
          </group>
          <group group_id="O2">
            <title>Group B: Pyronaridine/Artesunate (9:3 mg/kg)</title>
            <description>Pyronaridine tetraphosphate 9 mg/kg and artesunate 3 mg/kg&#xD;
Pyronaridine/artesunate: Tablets of fixed dose combination of pyronaridine and artesunate at a ratio of 3:1</description>
          </group>
          <group group_id="O3">
            <title>Group C: Pyronaridine/Artesunate (12:4 mg/kg)</title>
            <description>Pyronaridine tetraphsophate 12 mg/kg and artesunate 4 mg/kg&#xD;
Pyronaridine/artesunate: Tablets of fixed dose combination of pyronaridine and artesunate at a ratio of 3:1</description>
          </group>
        </group_list>
        <measure>
          <title>Adverse Events (AEs)</title>
          <description>An AE was defined as any unfavourable and unintended sign, symptom, syndrome, or illness that developed or worsened during the period of observation in the clinical study</description>
          <population>The safety population includes all subjects who were randomized and received any study medication, regardless of the amount.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="160"/>
                <count group_id="O2" value="157"/>
                <count group_id="O3" value="159"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Nr subj. with ≥1 AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="106"/>
                    <measurement group_id="O2" value="90"/>
                    <measurement group_id="O3" value="91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nr subj. with ≥1 treatment-related AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35"/>
                    <measurement group_id="O2" value="33"/>
                    <measurement group_id="O3" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nr subj. with ≥1 SAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nr subj. with ≥1 treatment-related SAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nr subj. with ≥1 AE leading to death</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nr subj. with ≥1 AE leading to study withdrawal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Day 0 to 42. Subjects experiencing AEs at Day 42 were followed for up to 30 days after the end of study or resolution of the event, whichever was earlier</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Group A: Pyronaridine/Artesunate (6:2 mg/kg)</title>
          <description>Pyronaridine tetraphosphate 6 mg/kg and artesunate 2 mg/kg&#xD;
Pyronaridine/artesunate: Tablets of fixed dose combination of pyronaridine and artesunate at a ratio of 3:1</description>
        </group>
        <group group_id="E2">
          <title>Group B: Pyronaridine/Artesunate (9:3 mg/kg)</title>
          <description>Pyronaridine tetraphosphate 9 mg/kg and artesunate 3 mg/kg&#xD;
Pyronaridine/artesunate: Tablets of fixed dose combination of pyronaridine and artesunate at a ratio of 3:1</description>
        </group>
        <group group_id="E3">
          <title>Group C: Pyronaridine/Artesunate (12:4 mg/kg)</title>
          <description>Pyronaridine tetraphsophate 12 mg/kg and artesunate 4 mg/kg&#xD;
Pyronaridine/artesunate: Tablets of fixed dose combination of pyronaridine and artesunate at a ratio of 3:1</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 9.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="159"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="160"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="159"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="160"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="159"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abscess Limb</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="160"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="159"/>
              </event>
              <event>
                <sub_title>Malaria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="160"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="159"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="159"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Hepatic enzyme increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="159"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Abortion incomplete</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="159"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_vocab>MedDRA 9.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="106" subjects_at_risk="160"/>
                <counts group_id="E2" subjects_affected="90" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="91" subjects_at_risk="159"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="16" subjects_affected="16" subjects_at_risk="160"/>
                <counts group_id="E2" events="15" subjects_affected="15" subjects_at_risk="157"/>
                <counts group_id="E3" events="13" subjects_affected="13" subjects_at_risk="159"/>
              </event>
              <event>
                <sub_title>Eosinophilia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="160"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="157"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="159"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="160"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="159"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="160"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="159"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="160"/>
                <counts group_id="E2" events="9" subjects_affected="7" subjects_at_risk="157"/>
                <counts group_id="E3" events="8" subjects_affected="8" subjects_at_risk="159"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="160"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="157"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="159"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="160"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="159"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="160"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="157"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="159"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="160"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="157"/>
                <counts group_id="E3" events="3" subjects_affected="2" subjects_at_risk="159"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="160"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="159"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="160"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="157"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="159"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="160"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="159"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="160"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="157"/>
                <counts group_id="E3" events="4" subjects_affected="3" subjects_at_risk="159"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="160"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="159"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="160"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="157"/>
                <counts group_id="E3" events="9" subjects_affected="8" subjects_at_risk="159"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="160"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="157"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="159"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="157"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="159"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="157"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="159"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="160"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="157"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="159"/>
              </event>
              <event>
                <sub_title>Malaria</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="160"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="157"/>
                <counts group_id="E3" events="7" subjects_affected="7" subjects_at_risk="159"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="160"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="157"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="159"/>
              </event>
              <event>
                <sub_title>Otitis media acute</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="160"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="159"/>
              </event>
              <event>
                <sub_title>Parasitic infection intestinal</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="160"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="157"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="159"/>
              </event>
              <event>
                <sub_title>Plasmodium falciparum infection</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="160"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="157"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="159"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="160"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="157"/>
                <counts group_id="E3" events="8" subjects_affected="7" subjects_at_risk="159"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Wound</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="157"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="159"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="160"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="157"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="159"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="160"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="159"/>
              </event>
              <event>
                <sub_title>Blood alkaline phosphatase increased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="160"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="159"/>
              </event>
              <event>
                <sub_title>Eosinophil count increased</sub_title>
                <counts group_id="E1" events="18" subjects_affected="17" subjects_at_risk="160"/>
                <counts group_id="E2" events="15" subjects_affected="14" subjects_at_risk="157"/>
                <counts group_id="E3" events="14" subjects_affected="14" subjects_at_risk="159"/>
              </event>
              <event>
                <sub_title>Transaminases increased</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="160"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="157"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="159"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="160"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="159"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="160"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="157"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="159"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="160"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="157"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="159"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="160"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="157"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="159"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="160"/>
                <counts group_id="E2" events="10" subjects_affected="8" subjects_at_risk="157"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="159"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="160"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="157"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="159"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="24" subjects_affected="22" subjects_at_risk="160"/>
                <counts group_id="E2" events="21" subjects_affected="19" subjects_at_risk="157"/>
                <counts group_id="E3" events="18" subjects_affected="17" subjects_at_risk="159"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="157"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="159"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Proteinuria</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="160"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="157"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="159"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Pelvic pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="160"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="159"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="160"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="157"/>
                <counts group_id="E3" events="14" subjects_affected="13" subjects_at_risk="159"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="157"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="159"/>
              </event>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="160"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="159"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="159"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperhidrosis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="160"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="157"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="159"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="160"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="157"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="159"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Stephan Duparc, MD, Chief Medical Officer</name_or_title>
      <organization>Medicines for Malaria Venture (MMV)</organization>
      <phone>+41 22 555 0300 ext 351</phone>
      <email>duparcs@mmv.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

